Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Deucravacitinib Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

NCT04877990
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Deucravacitinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Shreveport, Louisiana • Wyoming, Michigan • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

NCT03004768
View directory record Official record
Conditions
Psoriasis
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 2, 2026, 5:40 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

NCT04857034
View directory record Official record
Conditions
Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

NCT04086719
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
BMS-986165, Pyrimethamine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 2, 2026, 5:40 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris

NCT06444399
View directory record Official record
Conditions
Pityriasis Rubra Pilaris
Interventions
Deucravacitinib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

NCT03660436
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986165, MMF
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 2, 2026, 5:40 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Lancaster, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 5:40 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
50
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

NCT03890770
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

NCT03930602
View directory record Official record
Conditions
Healthy
Interventions
BMS-986165, Fluvoxamine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 2, 2026, 5:40 PM EDT
Terminated Phase 4 Interventional Results available

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

NCT06042920
View directory record Official record
Conditions
Palmoplantar Psoriasis, Genital Psoriasis
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
20
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 2, 2026, 5:40 PM EDT
Terminated Phase 2 Interventional Results available

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

NCT03943147
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-986165, Placebo, Mycophenolate Mofetil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
40
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

NCT06476834
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deucravacitinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 2, 2026, 5:40 PM EDT
Withdrawn Early Phase 1 Interventional

Deucravacitinib in PG

NCT05821374
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
Deucravacitinib
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

NCT03419910
View directory record Official record
Conditions
Psoriasis
Interventions
BMS-986165, Cyclosporine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 2, 2026, 5:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
39
States / cities
La Jolla, California • La Mesa, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

NCT06851871
View directory record Official record
Conditions
Healthy Participants
Interventions
Deucravacitinib, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 2, 2026, 5:40 PM EDT
Recruiting Phase 2 Interventional

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

NCT07335796
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMS-986165, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 2, 2026, 5:40 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo, Apremilast
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
24
States / cities
Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 2, 2026, 5:40 PM EDT
Terminated Phase 4 Interventional Results available

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

NCT05710185
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Deucravacitinib
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 2, 2026, 5:40 PM EDT
Recruiting No phase listed Observational

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

NCT05744466
View directory record Official record
Conditions
Psoriasis
Interventions
Deucravacitinib, Apremilast
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 2, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

NCT04055506
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986165, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 2, 2026, 5:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Assess Deucravacitinib Safety in Pregnancy

NCT07017699
View directory record Official record
Conditions
Psoriasis (PsO)
Interventions
Deucravacitinib, Other systemic treatments for PsO
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 2, 2026, 5:40 PM EDT